Thorough and transparent research studies conducted by a team work of experts in their own domain accomplish this global Sarcopenia Treatment Market research report. The report is valuable for both customary and emerging market players in the industry and provides in-depth market insights. This report is a great example of such wide-ranging market information which explores practical growth strategies and recommendations related to Pharmaceutical industry. This Sarcopenia Treatment Market research report serves the businesses with making enhanced decisions, deal with marketing of goods or services, and accomplish better profitability by prioritizing market goals.

Sarcopenia is a progressive skeletal muscle disorder. It involves the loss of muscle mass and strength due to natural aging process. This condition affects the gait and overall ability of body to perform normal tasks. According to International Osteoporosis Foundation (IOF), the muscle loss starts from the age of 40. The major causes of sarcopenia could be sedentary lifestyle, malnutrition and unhealthy food intake. The increasing population of people aged more than 60 and the increasing cases of malnutrition worldwide are the major factors augmenting the market growth.

Global Sarcopenia treatment market is rising gradually with a steady CAGR in the forecast period of 2019-2026. The growing prevalence of sarcopenia by increasing old age population and adoption of sedentary and unhealthy lifestyle is the major factor that contributes in the growth of global sarcopenia treatment market.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sarcopenia-treatment-market

Key Market Players:

Few of the major competitors currently working in the global sarcopenia treatment market are Novartis AG, AstaReal AB, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Biophytis, Metabolic Technologies, Inc., AbbVie Inc., Danone, Pfizer Inc., Abbott, Biogen, GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Nestlé, Mitacs, Sanofi, Bayer AG, Amway, Zydus Cadila, Eli Lilly and Company, Radius Health, Inc., MYSURABLE S.R.L., PhaseBio Pharmaceuticals, Inc among others.

Market Drivers

 Prevelance of geriatric population is expected to boost the market growth
Increasing adoption of vitamins and dietary supplements among the ageing population for better treatment of this disorder also acts as a market driver The prevalence of sarcopenia is high among old age population drives the global sarcopenia treatment market
Surging research and development activities for the treatment of sarcopenia also acts as a driver for this market
Rising cases of malnutrition due to poor nutritional intake can also augment the growth of this market

Market Restraints

Lack of awareness among people regarding the muscle loss can act as a major restraint for this market
Lack of skilled medical profession for the diagnosis of this disorder is also less; this factor can also restrict the growth of this market
High cost of protein supplement and unavailability of sarcopenia treatment drugs can also impede the market growth

Segmentation: Global Sarcopenia Treatment Market

By Treatment

Medication
Vitamin/ Dietary Supplements
Others

By Route of Administration

Oral
Injectable

 By End Users

Hospitals
Homecare
Specialty Clinics
Others

By Distribution Channels

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others

By Geography

North America
U.S.
Canada
Mexico
South America
Brazil
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-sarcopenia-treatment-market

Key Developments in the Market:

In April 2019. MYSURABLE S.R.L., has developed mioTest, a system based on effective and scientifically validated tools that identifies the risk of sarcopenia. The system can also assess muscle mass composition including functionality and level of hydration of muscles in a beneficial and non-invasive way
In April 2019, PhaseBio Pharmaceuticals, Inc. licensed ImmunoForge, Co. Ltd. the global rights for PB1023, a recombinant GLP-1 analogue used for the treatment of patients with sarcopenia. ImmunoForge, Co. Ltd. is working on a pipeline for development of novel therapies for sarcopenia related diseases. PhaseBio Pharmaceuticals, Inc. will receive development milestone payments and royalty payments on the sales of the product by this licensed agreement

Competitive Analysis:

Global sarcopenia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of sarcopenia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.